Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Conclusion: Addition of Nivo to (I+A) induction is feasible and safe in younger AML pts. Post-transplant severe GVHD is not significantly increased and is manageable. CD4+ T-effector cells display exhausted phenotype in non-responders that can be potentially reversed. Studies with earlier initiation of checkpoint inhibitor therapy are plannedFigure.DisclosuresDaver: Novartis: Research Funding; ARIAD: Research Funding; Novartis: Consultancy; BMS: Research Funding; Sunesis: Consultancy; Incyte: Research Funding; Karyopharm: Consultancy; Alexion: Consultancy; Daiichi-Sankyo: Research Funding; Kiromic: Research Funding; Pfizer: Consultancy; ImmunoGen: Consultancy; Incyte: Consultancy; Pfizer: Research Funding; Sunesis: Research Funding; Karyopharm: Research Funding; Otsuka: Consultancy. Thompson: Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Research Funding; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Kadia: Amgen: Consultancy, Research Funding; Celgene: Research Funding; BMS: Research Funding; Celgene: Research Funding; Takeda: Consultancy; Abbvie: Consultancy; Novartis: Consultancy; Abbvie: Consultancy; Amgen: Consultancy, Research Funding; BMS: Research Funding; Jazz: Consultancy, Research Funding; Pfizer: ...
Source: Blood - Category: Hematology Authors: Assi, R., Kantarjian, H. M., Daver, N. G., Garcia-Manero, G., Benton, C. B., Thompson, P. A., Borthakur, G., Kadia, T. M., Alvarado, Y., Jabbour, E. J., Konopleva, M. Y., Takahashi, K., Kornblau, S. M., DiNardo, C. D., Estrov, Z. E., Flores, W., Basu, S., Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Immunotherapy Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Chemotherapy | Genetics | Immunotherapy | Insurance | Leukemia | Myelodysplastic Syndrome | Pancreatitis | Pfizer | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants